# Michael Thomas

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-thomas/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,231 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 76 |
| i10-index | 279 |
| Last Known Institution | Barwon Health |
| OpenAlex ID | https://openalex.org/A5101492076 |
| ORCID iD | https://orcid.org/0000-0001-9511-055X |
| Works | 721 |

## Researcher papers

- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival](https://scholariq.org/papers/the-novel-histologic-international-association-for-the-study-of-lung-cancer/)
- [Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial](https://scholariq.org/papers/activity-and-safety-of-ceritinib-in-patients-with-alk-rearranged-non-small-cell/)
- [Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study](https://scholariq.org/papers/pralsetinib-for-ret-fusion-positive-non-small-cell-lung-cancer-arrow-a-multi/)
- [Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians](https://scholariq.org/papers/implementing-tumor-mutational-burden-tmb-analysis-in-routine-diagnostics-a/)
- [AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients](https://scholariq.org/papers/aurka-dlgap5-tpx2-kif11-and-ckap5-five-specific-mitosis-associated-genes/)
- [Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial](https://scholariq.org/papers/afatinib-beyond-progression-in-patients-with-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Barwon Health](https://scholariq.org/institutions/barwon-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.